BioNTech SE

NasdaqGS:BNTX Stock Report

Market Cap: US$25.9b

BioNTech Valuation

Is BNTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BNTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BNTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BNTX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BNTX?

Key metric: As BNTX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BNTX. This is calculated by dividing BNTX's market cap by their current revenue.
What is BNTX's PS Ratio?
PS Ratio8.6x
Sales€3.04b
Market Cap€24.92b

Price to Sales Ratio vs Peers

How does BNTX's PS Ratio compare to its peers?

The above table shows the PS ratio for BNTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.1x
MRNA Moderna
3.1x6.8%US$14.7b
BIIB Biogen
2.4x1.3%US$23.0b
CRSP CRISPR Therapeutics
20.1x54.3%US$4.0b
SGEN Seagen
18.8x22.6%US$43.2b
BNTX BioNTech
8.6x3.4%US$25.9b

Price-To-Sales vs Peers: BNTX is good value based on its Price-To-Sales Ratio (8.6x) compared to the peer average (11.1x).

Price to Sales Ratio vs Industry

How does BNTX's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
4x2.4%US$111.86b
BIIB Biogen
2.4x1.3%US$23.03b
MRNA Moderna
3.1x6.8%US$14.72b
INCY Incyte
3.4x8.9%US$13.56b
BNTX 8.6xIndustry Avg. 9.7xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BNTX is good value based on its Price-To-Sales Ratio (8.6x) compared to the US Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is BNTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BNTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.6x
Fair PS Ratio6.5x

Price-To-Sales vs Fair Ratio: BNTX is expensive based on its Price-To-Sales Ratio (8.6x) compared to the estimated Fair Price-To-Sales Ratio (6.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BNTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$113.13
US$136.49
+20.6%
9.5%US$171.25US$120.68n/a18
Nov ’25US$111.48
US$129.04
+15.8%
17.1%US$170.67US$89.21n/a18
Oct ’25US$119.93
US$123.86
+3.3%
19.6%US$170.83US$84.91n/a18
Sep ’25US$88.22
US$110.95
+25.8%
20.4%US$174.00US$86.49n/a18
Aug ’25US$80.68
US$111.62
+38.3%
20.3%US$171.09US$90.14n/a18
Jul ’25US$78.83
US$110.58
+40.3%
20.2%US$170.43US$89.21n/a18
Jun ’25US$100.60
US$111.66
+11.0%
20.4%US$171.87US$90.17n/a18
May ’25US$89.95
US$114.10
+26.8%
20.7%US$168.57US$89.10n/a18
Apr ’25US$93.12
US$117.29
+26.0%
23.6%US$186.95US$89.84n/a18
Mar ’25US$90.94
US$126.43
+39.0%
22.5%US$187.90US$98.86n/a17
Feb ’25US$94.51
US$126.87
+34.2%
22.4%US$187.19US$98.49n/a16
Jan ’25US$105.54
US$132.42
+25.5%
21.0%US$185.60US$100.28n/a16
Dec ’24US$99.40
US$134.68
+35.5%
23.0%US$198.93US$99.13n/a17
Nov ’24US$93.45
US$139.39
+49.2%
23.1%US$193.30US$101.82US$111.4817
Oct ’24US$108.64
US$146.17
+34.5%
22.9%US$196.79US$99.21US$119.9316
Sep ’24US$121.75
US$154.98
+27.3%
26.1%US$247.56US$98.60US$88.2217
Aug ’24US$107.13
US$162.25
+51.4%
24.7%US$251.54US$109.06US$80.6817
Jul ’24US$107.93
US$166.15
+53.9%
23.1%US$249.62US$108.22US$78.8316
Jun ’24US$104.12
US$161.13
+54.8%
23.4%US$245.51US$106.44US$100.6017
May ’24US$111.99
US$178.28
+59.2%
23.7%US$263.31US$128.00US$89.9517
Apr ’24US$124.57
US$183.95
+47.7%
22.2%US$260.34US$130.79US$93.1216
Mar ’24US$127.48
US$203.69
+59.8%
23.4%US$293.87US$139.63US$90.9415
Feb ’24US$143.05
US$211.95
+48.2%
23.5%US$306.00US$145.89US$94.5115
Jan ’24US$150.22
US$213.83
+42.3%
23.2%US$328.94US$152.71US$105.5415
Dec ’23US$169.47
US$209.30
+23.5%
22.4%US$317.11US$147.97US$99.4016
Nov ’23US$144.08
US$209.50
+45.4%
24.6%US$314.06US$131.87US$93.4516

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$35.9b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

4.7%

1Y

-4.8%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.91

7D

0.6%

1Y

9.8%